Search Results

VITEK® 2 Streptococcus Tetracycline is designed for antimicrobial susceptibility testing of Streptococcus species. VITEK 2 Streptococcus Tetracycline is a quantitative test intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. Tetracycline has an antimicrobial activity against the microorganisms listed below, according to the FDA label for this antimicrobial.

Active in vitro and in clinical infections Streptococcus pneumoniae Streptococcus pyogenes Viridans group streptococci

The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 System for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp. and clinically significant yeast.

The VITEK® 2 AST cards are essentially miniaturized versions of the doubling dilution technique for determining the minimum inhibitory concentration (MIC) microdilution methodology. The isolate to be tested is diluted to a standardized concentration with 0.45% to 0.50% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK® 2 automatically fills, seals and places the card into the incubator/reader. The VITEK® 2 Compact has a manual filling. sealing and loading operation. The VITEK 2 Systems monitor the growth of each well in the card over a defined period of time (up to 36 hours for yeast). At the completion of the incubation cycle, a report is generated that contains the MIC value along with the interpretive category result for each antimicrobial contained on the card.

Here's an analysis of the acceptance criteria and study proving the device meets them, based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Size and Data Provenance for the Test Set

• Sample Size: The document states that the external evaluation was conducted with "fresh and stock clinical isolates, as well as a set of challenge strains." However, specific numerical sample sizes for these categories are not provided.
• Data Provenance: The text does not explicitly state the country of origin for the data. It also doesn't explicitly state whether the clinical isolates were retrospective or prospective, though the mention of "fresh clinical isolates" implies prospective collection for at least some portion of the data.

3. Number of Experts and Qualifications for Establishing Ground Truth (Test Set)

• The document states that performance was compared to the "CLSI broth microdilution reference method." The CLSI method itself is considered the gold standard and thus represents the ground truth.
• Number of Experts: This method does not typically involve "experts" in the sense of human readers adjudicating results. Instead, it relies on standardized laboratory procedures and measurements.
• Qualifications of Experts: Not applicable, as the ground truth is established by a standardized reference method rather than human expert consensus.

4. Adjudication Method for the Test Set

• None in the traditional sense. The ground truth is the CLSI broth microdilution reference method. Adjudication between human experts is not relevant here as the comparison is between the automated VITEK® 2 system and a standardized laboratory method. The "agreement" metrics (essential and category) are direct comparisons of the VITEK® 2's results to the CLSI results.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

• No, an MRMC comparative effectiveness study was not done. This study evaluates the performance of an automated susceptibility test system against a reference laboratory method, not the improvement of human readers with AI assistance.

6. Standalone Performance

• Yes, a standalone study was done. The entire study described focuses on the performance of the VITEK® 2 Streptococcus Tetracycline device (the algorithm/system itself) in determining antimicrobial susceptibility, without human intervention in interpreting the results once the system has processed the sample. The results (Essential Agreement and Category Agreement) are direct measures of the algorithm's performance against the reference method.

7. Type of Ground Truth Used

• CLSI broth microdilution reference method. This is a recognized laboratory standard method for determining minimum inhibitory concentration (MIC) and interpretive categories for antimicrobial susceptibility.

8. Sample Size for the Training Set

• The document does not explicitly state the sample size for the training set. It only describes the external evaluation for performance confirmation.

9. How the Ground Truth for the Training Set Was Established

• The document does not explicitly state how the ground truth for the training set was established. Given that the VITEK® 2 is an established platform, it's highly probable that training involved extensive data generation using similar gold standard reference methods (like CLSI broth microdilution) to develop and calibrate the interpretive algorithms. However, this information is not present in the provided text.

Ask a specific question about this device